Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy.
cyclophosphamide
focal segmental glomerulosclerosis
glucocorticoids
renal biopsy
rituximab
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
02
06
2022
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Focal segmental glomerular sclerosis (FSGS) is a histologic lesion rather than a specific disease entity and represents a cluster of different conditions affecting both children and adults that includes primary, secondary and genetically mediated forms. These forms can be distinguished by electron microscopy and genetic assessment and show different responsiveness to steroids and immunosuppressants. Despite some promising effects of rituximab in nephrotic syndrome in children, the results in adults with FSGS are disappointing. Our group previously explored the effectiveness of rituximab in eight adult patients with unselected forms of FSGS and achieved a consistent reduction in proteinuria in one case. Following this experience, we developed an alternative therapeutic option intended to enhance the potential of rituximab with the support of other synergic drugs. We herein report the results of this therapeutic protocol (six administrations of rituximab plus two of intravenous cyclophosphamide plus glucocorticoids) in seven prospectively enrolled patients with extensive podocyte effacement and recurrent relapses or steroid dependence. Patients had a median baseline serum creatinine level of 2.2 mg/dl (range 1-4.7) that decreased to 1.1 mg/dl (range 0.9-2.2) and 1.1 mg/dl (range 0.75-2.21) after 3 and 6 months, respectively, and remained unchanged at 12 months. Three of five patients with renal failure turned to normal function while the other two patients maintained a stable impairment after 18 and 52 months. The median proteinuria decreased from 6.1 g/24 h to 3.5, 3.5 and 1.9 g/24 h at 3, 6 and 12 months, respectively. Specifically, five of seven patients had a partial response at 12 months and became non-nephrotic. One of them had a complete response at 18 months and was still in complete remission at the last follow-up visit at 36 months. Proteinuria persisted unchanged in two of seven patients with a genetic-related disease. No serious late adverse events were observed. Our results show that intensive B-cell depletion therapy is able to reverse the nephrotic syndrome of steroid-dependent or frequently relapsing adult patients with putatively idiopathic FSGS (i.e. with extensive podocyte effacement).
Sections du résumé
Background
UNASSIGNED
Focal segmental glomerular sclerosis (FSGS) is a histologic lesion rather than a specific disease entity and represents a cluster of different conditions affecting both children and adults that includes primary, secondary and genetically mediated forms. These forms can be distinguished by electron microscopy and genetic assessment and show different responsiveness to steroids and immunosuppressants. Despite some promising effects of rituximab in nephrotic syndrome in children, the results in adults with FSGS are disappointing. Our group previously explored the effectiveness of rituximab in eight adult patients with unselected forms of FSGS and achieved a consistent reduction in proteinuria in one case. Following this experience, we developed an alternative therapeutic option intended to enhance the potential of rituximab with the support of other synergic drugs. We herein report the results of this therapeutic protocol (six administrations of rituximab plus two of intravenous cyclophosphamide plus glucocorticoids) in seven prospectively enrolled patients with extensive podocyte effacement and recurrent relapses or steroid dependence.
Results
UNASSIGNED
Patients had a median baseline serum creatinine level of 2.2 mg/dl (range 1-4.7) that decreased to 1.1 mg/dl (range 0.9-2.2) and 1.1 mg/dl (range 0.75-2.21) after 3 and 6 months, respectively, and remained unchanged at 12 months. Three of five patients with renal failure turned to normal function while the other two patients maintained a stable impairment after 18 and 52 months. The median proteinuria decreased from 6.1 g/24 h to 3.5, 3.5 and 1.9 g/24 h at 3, 6 and 12 months, respectively. Specifically, five of seven patients had a partial response at 12 months and became non-nephrotic. One of them had a complete response at 18 months and was still in complete remission at the last follow-up visit at 36 months. Proteinuria persisted unchanged in two of seven patients with a genetic-related disease. No serious late adverse events were observed.
Conclusions
UNASSIGNED
Our results show that intensive B-cell depletion therapy is able to reverse the nephrotic syndrome of steroid-dependent or frequently relapsing adult patients with putatively idiopathic FSGS (i.e. with extensive podocyte effacement).
Identifiants
pubmed: 37529640
doi: 10.1093/ckj/sfac207
pii: sfac207
pmc: PMC10387391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1258-1264Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
None declared.
Références
Nat Rev Nephrol. 2021 Sep;17(9):619-630
pubmed: 34017116
Curr Rheumatol Rep. 2017 Feb;19(2):6
pubmed: 28155022
Nephrol Dial Transplant. 2015 Mar;30(3):375-84
pubmed: 24589721
Clin J Am Soc Nephrol. 2009 Aug;4(8):1317-23
pubmed: 19578004
Intern Med. 2012;51(7):759-62
pubmed: 22466834
Arthritis Rheum. 2009 Sep 15;61(9):1281-2
pubmed: 19714598
Wien Klin Wochenschr. 2013 Jun;125(11-12):328-33
pubmed: 23624956
J Clin Med. 2021 Jan 14;10(2):
pubmed: 33466837
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517
pubmed: 28242845
Arthritis Rheum. 2009 Apr 15;61(4):482-7
pubmed: 19333973
J Am Soc Nephrol. 2004 Aug;15(8):2169-77
pubmed: 15284302
Clin Kidney J. 2020 Nov 21;14(4):1042-1054
pubmed: 34094516
Clin Rheumatol. 2019 Nov;38(11):2977-2994
pubmed: 31367943
Clin Kidney J. 2014 Dec;7(6):531-7
pubmed: 25503953
Kidney Int Rep. 2021 Feb 03;6(4):1081-1087
pubmed: 33912758
J Am Soc Nephrol. 2014 Apr;25(4):850-63
pubmed: 24480824
Am J Nephrol. 2017;46(2):108-113
pubmed: 28700988
Front Immunol. 2022 Mar 24;13:777134
pubmed: 35401565
Cureus. 2021 Nov 8;13(11):e19363
pubmed: 34925975
Kidney Int Rep. 2021 Oct 30;7(1):68-77
pubmed: 35005315
Ann Rheum Dis. 2008 Mar;67(3):330-4
pubmed: 17827182